Payment overview · 2025
General Payments
$342.34
19 reported records · 10 companies
Healthcare provider profile · identity verified
Lisa Forehand, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAMBURG, NY · NPI 1538127113
Verified facts
What the public records show
CMS Open Payments records show Lisa Forehand, MD received $342.34 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus, Trelegy Ellipta.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $96.30 | 28.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.17 | 15.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.40 | 13.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $42.20 | 12.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.60 | 6.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $19.22 | 5.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.23 | 5.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.34 | 4.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.33 | 4.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.55 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $342.34 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $96.30 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.17 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.40 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.77 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 396 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 371 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 340 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 301 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 293 | 103 |
| Losartan Potassium | Losartan Potassium | 238 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 231 | 75 |
| Omeprazole | Omeprazole | 182 | 66 |
| Gabapentin | Gabapentin | 168 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 37 |
| Furosemide | Furosemide | 129 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 49 |
| Lisinopril | Lisinopril | 123 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 114 | 34 |
| Metformin Hcl | Metformin Hcl | 114 | 35 |
| Meloxicam | Meloxicam | 113 | 37 |
| Trazodone Hcl | Trazodone Hcl | 113 | 29 |
| Potassium Chloride | Potassium Chloride | 110 | 37 |
| Carvedilol | Carvedilol | 109 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 39 |
| Famotidine | Famotidine | 99 | 38 |
| Simvastatin | Simvastatin | 95 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 90 | 23 |
| Alendronate Sodium | Alendronate Sodium | 88 | 28 |
| Mounjaro | Tirzepatide | 80 | 15 |
| Eliquis | Apixaban | 73 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 30 |
| Metformin Hcl Er | Metformin Hcl | 66 | 25 |
| Jardiance | Empagliflozin | 64 | 14 |
| Enalapril Maleate | Enalapril Maleate | 59 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Sertraline Hcl | Sertraline Hcl | 52 | 18 |
| Trulicity | Dulaglutide | 51 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 48 | 11 |
| Buspirone Hcl | Buspirone Hcl | 46 | 14 |
| Allopurinol | Allopurinol | 45 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 13 |
| Terazosin Hcl | Terazosin Hcl | 42 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Clonidine | Clonidine | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 30 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 14 |
| Ozempic | Semaglutide | 31 | 12 |
| Felodipine Er | Felodipine | 30 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | 12 |
| Celecoxib | Celecoxib | 28 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 24 | 11 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | 11 |
| Montelukast Sodium | Montelukast Sodium | 23 | 11 |
| Prednisone | Prednisone | 23 | 19 |
| Alprazolam | Alprazolam | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Estradiol | Estradiol | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 17 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 14 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | 12 |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $342.34 · 19 records | AstraZeneca Pharmaceuticals LP | AREXVY, AUSTEDO XR, CAPVAXIVE, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, JARDIANCE, Kerendia, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error